G2GBIO지투지바이오

G2GBIO shares have rallied sharply on a China partnership, but the company still reports heavy losses and a thin revenue base.

G2GBIO is a long-acting drug delivery company whose revenue comes mainly from technology licensing, joint development, research services and contract manufacturing. Over the trailing twelve months to H1 2026 it reported revenue of about ₩2.2B against an operating loss of about ₩12.6B, and the share price closed at ₩49,700 on 2026-10-23, still well below its 52-week high of ₩124,000. Recent gains are tied to news flow rather than to a change in the reported financials.

What stands out

• Trailing revenue of ₩2.2B is small against an operating loss of ₩12.6B and a net loss of ₩14.9B, giving a net margin of about -675%.
• Revenue fell about 45% in 2025 to ₩423M, after ₩769M in 2024, and 2024 net loss was ₩83B.
• Cash of ₩12.1B sits against borrowings of ₩37.5B, and free cash flow over the period was about -₩15.7B.
• Shares are up 55% over one month and 60% over three months, yet down 17% over one year; price-to-book is 5.9 and there is no meaningful earnings-based P/E.
• Recent headlines centre on partnership and evaluation deals with China's UBT and a Chinese pharma contract; the data does not show the financial terms of these deals.
• Foreign ownership fell from 8.4% to 4.3% over 60 days, while the 20-day flows show foreign and retail net selling and institutional net buying.

What to watch

• Whether the China partnerships convert into signed licensing or development contracts with disclosed value, which the data does not yet show.
• Filings on convertible preferred share conversion price adjustments, which may signal dilution, and the 2026 management-matter disclosures flagged on 2026-08-27 and 2026-10-19 (details not in the data).
• The next periodic results, since losses and borrowings remain large relative to cash and revenue.